Tapan Kadia

Just wrapped up an incredible ASH convention! Grateful for the opportunity to be part of the leukemia fellowship @MDAndersonNews @garciamanero @TapKadia @r_sazevedo #leukemia #ASH25 @Apsingh_MD

Great presentation by @jenweiying summarizing the frontline data with Oral Dac Ven Revumenib in patients with newly diagnosed NPM1-m and KMT2a-r AML. #ASH2025 @MDAndersonNews

Big thanks to Drs. David A. Sallman, @Tapkadia and @dremmasearle for an outstanding #ASH25 #AML session—packed with practical insights for everyday clinical care. 📺 Catch the replay: bit.ly/2025-AML-T Grateful for grant support from @JNJInnovMed, @kuraoncology and @Syndax, and for our collaboration with @HealthTree! #CME #MedEd

#ASH25 | Wow!! Thanks 🙏 to @ASH_hematology for featuring our @MDAndersonNews Leukemia team in the #ASH25 Program Guide with the reminder save the date for #ASH26 !!!!! | @TapKadia @drsangeetmd @JenMarvinPeek @HannahGoulart @doctorpemm @CRausch_PharmD @FadiHaddad_MD @NitinJainMD

Our latest from @MDAndersonNews sharing the largest series of these cases to date. onlinelibrary.wiley.com/doi/10.1111/bj… @jenweiying @TapKadia @BrJHaem

Read the cell, guess the genetics. #HemePath #Genetics #leusm #AMLsm 🔬🧬🩸

We report incidence of NPM1-wildtype relapses in pts treated with VEN-based frontline tx in AML.   🔴Overall, absolute # of relapses in NPM1 AML after VEN is ⬇️  🔴the fraction of NPM1-wildtype relapses ⬆️ with the⬆️ intensity of chemo backbone added to VEN.  🔴 NPM1 wildtype relapses occur later and often had MR mutations.  And ALL (8/8) had a different flow immunophenotype compared to original AML.  🔴We proposed that these were ‘new’ AMLs, that arose from common preleukemic (CH) precursor, but that the original NPM1-mutated AML was ‘cured’. onlinelibrary.wiley.com/action/oidcSta… @AjHematology

Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory #AML @TapKadia @AjHematology sohoinsider.com/leukemia/acute…

Triplet therapy maintains, improves quality of life in relapsed/refractory myeloma sohoinsider.com/news/belantama…

Very much looking forward to this meeting. Looking forward to great discussions and presentations from key US and international leaders on AML & ALL. Hoping you can join! @_MDEducation @jaltmanmd @TapKadia @doctorpemm @Ramikomrokji

👉 Check the Top #ALL #abstracts at #EHA2025 by date and ID Many presented by our #Leukemia Faculty from @MDAndersonNews Looking forward to exciting discussions & new treatment options for patients at @EHA_Hematology @OncoAlert @ALL_Hub_ #leusm

👉 Check the Top #AML #abstracts at #EHA2025 by date and ID Many presented by our #Leukemia Faculty & Fellows from @MDAndersonNews Looking forward to exciting discussions & new treatment options for patients at @EHA_Hematology @OncoAlert @AML_Hub #leusm

👉👉👉Wonderful to get to spend some time with our friend & colleague @CRausch who is back in town this weekend ! @Marxk @TapKadia | #leusm

👉👉👉Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis | Led by .@Daver_Leukemia & @HusseinAbbasLab aacrjournals.org/clincancerres/… | @MDAndersonNews #leusm #endcancer @CCR_AACR @CD_AACR

@doctorpemm @Aiims1742 @nyulangone @Perlmutter_CC @NitinJainMD @Daver_Leukemia @GBorthakur Congrats @Aiims1742 !

@Aiims1742 @nyulangone @Perlmutter_CC Congratulations @Aiims1742 !!! @NitinJainMD @Daver_Leukemia @TapKadia @GBorthakur

🤠 👉🏽 🗽 news: I will be joining @nyulangone on September 1, 2025 as Director of the GI Cancer Center & Associate Director of Translational Research at @Perlmutter_CC. I am excited to start the next chapter of the Maitra Lab in NYC & build a strong GI cancer research program.

@Aiims1742 @nyulangone @Perlmutter_CC Congratulations @Aiims1742 ! We’ll miss you at MDACC

👉👉👉Our group’s new article led by Dr @HannahGoulart & Dr @TapKadia Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia AML acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… | @JournalCancer @MDAndersonNews #leusm #endcancer | @sanamloghavi

CLIA for patients with relapsed and/or refractory AML - @doctorpemm @HannahGoulart @TapKadia @gchantada @sanamloghavi oncodaily.com/url/278223 #CLIA #AML #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer

First report of the Ph 2 trial of the CLIA regimen in pts w/ R/R #AML: CR/CRi of 49% & median OS of 12 months in pts who received it as 1st salvage rx. Data provides tolerable & effective backbone upon which to build combination strategies @JournalCancer doi.org/10.1002/cncr.3…

New research from @MDAndersonNews investigators presents outcomes in FLT3-mutated acute myeloid leukemia acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @AlexBataller @TapKadia @Daver_Leukemia @NicholasShortMD @MusaYilmazMD @GBorthakur @GhayasIssa @DrHKantarjian @OncoAlert #LeuSM #AML